

Bayesian causal network modeling suggests adolescent cannabis use accelerates prefrontal cortical thinning

Max M Owens, Matthew D Albaugh, Nicholas Allgaier, Dekang Yuan, Gabriel Robert, Renata Basso Cupertino, Philip A. Spechler, Anthony Juliano, Sage Hahn, Tobias Banaschewski, et al.

▶ To cite this version:

Max M Owens, Matthew D Albaugh, Nicholas Allgaier, Dekang Yuan, Gabriel Robert, et al.. Bayesian causal network modeling suggests adolescent cannabis use accelerates prefrontal cortical thinning. Translational Psychiatry, 2022, 12 (1), pp.188. 10.1038/s41398-022-01956-4. inserm-03933612

HAL Id: inserm-03933612 https://inserm.hal.science/inserm-03933612

Submitted on 10 Jan2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ARTICLE OPEN Bayesian causal network modeling suggests adolescent

Check for updates

cannabis use accelerates prefrontal cortical thinning

Max M. Owens ^[1]^[2], Matthew D. Albaugh¹, Nicholas Allgaier ^[1], Dekang Yuan¹, Gabriel Robert^{2,3,4}, Renata B. Cupertino¹, Philip A. Spechler ^[5], Anthony Juliano ^[1], Sage Hahn¹, Tobias Banaschewski ^[0], Arun L. W. Bokde ^[0], Sylvane Desrivières ^[0], Herta Flor^{9,10}, Antoine Grigis¹¹, Penny Gowland ^[1], Andreas Heinz ^[1], Rüdiger Brühl ^[1], Jean-Luc Martinot ^{[15}, Marie-Laure Paillère Martinot^{16,17}, Eric Artiges ^[18], Frauke Nees ^[6], Dimitri Papadopoulos Orfanos ^[11], Herve Lemaitre^{11,20}, Tomáš Paus ^[0], ^{21,22,23}, Luise Poustka²⁴, Sabina Millenet⁶, Juliane H. Fröhner ^[0], ²⁵, Michael N. Smolka ^[0], Henrik Walter ^[1], Robert Whelan ^{[126}, Scott Mackey¹, Gunter Schumann ^[0], ^{27,28}, Hugh Garavan¹ and The IMAGEN Consortium*

© The Author(s) 2022

While there is substantial evidence that cannabis use is associated with differences in human brain development, most of this evidence is correlational in nature. Bayesian causal network (BCN) modeling attempts to identify probable causal relationships in correlational data using conditional probabilities to estimate directional associations between a set of interrelated variables. In this study, we employed BCN modeling in 637 adolescents from the IMAGEN study who were cannabis naïve at age 14 to provide evidence that the accelerated prefrontal cortical thinning found previously in adolescent cannabis users by Albaugh et al. [1] is a result of cannabis use causally affecting neurodevelopment. BCNs incorporated data on cannabis use, prefrontal cortical thickness, and other factors related to both brain development and cannabis use, including demographics, psychopathology, childhood adversity, and other substance use. All BCN algorithms strongly suggested a directional relationship from adolescent cannabis use to accelerated cortical thinning. While BCN modeling alone does not prove a causal relationship, these results are consistent with a body of animal and human research suggesting that adolescent cannabis use adversely affects brain development.

Translational Psychiatry (2022)12:188; https://doi.org/10.1038/s41398-022-01956-4

INTRODUCTION

There is substantial evidence that adolescent cannabis use is associated with poorer cognitive function [2], as well as differences in brain structure and function [3]. However, evidence is mixed as to whether the cognitive and neurobiological differences identified are caused by adolescent cannabis use or are pre-existing and might dispose individuals to be more likely to initiate cannabis use. Research in humans suggests that long-term differences in prefrontal morphometry in adolescents using cannabis are most pronounced in regions of the brain that show

¹Department of Psychiatry, University of Vermont Larner College of Medicine, Burlington, VT, USA. ²Psychiatry Department, University of Rennes 1, Rennes, France. ³Adult University Psychiatry Department, Guillaume Régnier Hospital, Rennes, France. ⁴U1288 Empenn, UMR 6074, IRISA, Rennes, France. ⁵Laureate Institute for Brain Research, Tulsa, OK, USA. ⁶Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. ⁷Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland. ⁸Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, London, UK. 9Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, Mannheim, Germany. ¹⁰Department of Psychology, School of Social Sciences, University of Mannheim, Mannheim, Germany. ¹¹NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France. ¹²Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK. 13 Department of Psychiatry and Psychotherapy Campus Charité Mitte, Charité-Universitätsmedizin, corporate member of Freie Universität Berlin & Humboldt-Universität zu Berlin, Berlin, Germany.¹⁴Physikalisch-Technische Bundesanstalt (PTB), Braunschweig and Berlin, Braunschweig, Germany.¹⁵Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Gif-sur-Yvette, France. ¹⁶Institut National de la Santé et de la Recherce Médicale, INSERM U A10 "Trajectoires développementales & psychiatrie", University Paris-Saclay, Ecole Normale Supérieure Paris-Saclay, CNRS; Centre Borelli, Gif-sur-Yvette, France. ¹⁷AP-HP. Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France. 18 Institut National de la Santé et de la Recherche Médicale, INSERM U1299 "Trajectoires développementales en psychiatrie"; Ecole Normale supérieure Paris-Saclay, Université Paris-Saclay, Université de Paris, Centre Borelli; Gif-sur-Yvette, & Department of Psychiatry, EPS Barthélémy Durand, Etampes, France. ¹⁹Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, Kiel, Germany. ²⁰Institut des Maladies Neurodégénératives, CNRS UMR 5293, Université de Bordeaux, Centre Broca Nouvelle-Aquitaine, Bordeaux, France. ²¹Departments of Psychiatry and Neuroscience, Faculty of Medicine and Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, QC, Canada. ²²Departments of Psychology, University of Toronto, Toronto, ON, Canada. ²³Department of Psychiatry, University of Toronto, Toronto, ON, Canada. ²⁴Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen, von-Siebold-Str. 5, 37075 Göttingen, Germany. 25 Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.²⁶School of Psychology and Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland.²⁷Centre for Population Neuroscience and Stratified Medicine (PONS), Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany. ²⁸Centre for Population Neuroscience and Precision Medicine (PONS), Institute for Science and Technology of Brain-inspired Intelligence (ISTBI), Fudan University, Shanghai, China. *A list of authors and their affiliations appears at the end of the paper. [™]email: owensmax03@gmail.com

Received: 3 December 2021 Revised: 18 April 2022 Accepted: 22 April 2022 Published online: 06 May 2022

the highest levels of expression for the cannabinoid receptor 1 gene (CNR1) [4]. Additionally, animal research has shown that THC exposure in adolescent rats alters the morphological trajectory of pyramidal neurons in the prefrontal cortex [5]. However, adult and older adolescent twin studies have found comparable cognitive function in monozygotic twins discordant for cannabis use, though these studies have not investigated brain structure or function [6, 7].

A recent paper by Albaugh et al. [1] found that, in a sample of 799 adolescents, initiation of cannabis use between the ages of 14 and 19 was associated with a higher rate of cortical thinning during that period. In that study, there were no differences in cortical thickness among the groups at age 14 and the subsequent cortical thinning was associated with amount of cannabis used from 14 to 19 in a dose-dependent pattern. It also found that regions demonstrating cannabis-related cortical thinning had, on average, greater availability of CB1 receptors (as assessed by Positron Emission Tomography in a separate sample of young adults), suggesting that the accelerated thinning may be mediated, in part, by cannabis exposure affecting the brain's endogenous cannabinoid system. That said, it remains possible that these brain changes may not be a consequence of the cannabis exposure but may reflect instead a neurodevelopmental trajectory caused by other factors that is related to a higher likelihood of adolescent cannabis use.

Cortical thinning in adolescence is well-established as a normal trajectory of brain development. Studies estimate cortical thinning of around 1% annually, which comes out to around 0.03–0.06 millimeters per year [8–11]. There is also work showing that negative early life experiences are associated with premature thinning in adolescence [12], which is, in turn, associated with negative outcomes, including greater likelihood of attention-deficit/hyperactivity symptoms [13] and symptoms of depression [14]. Likewise, Albaugh et al. found an association between accelerated cortical thinning and attentional impulsivity, particularly in the DPFC region identified as being related to cannabis use [1]. In total, this literature suggests that accelerated prefrontal thinning resulting from cannabis use is likely to be a negative prognostic factor for mental health outcomes.

Bayesian causal network (BCN) modeling is a method for estimating the directional relationships between a set of differentially related variables [15]. This approach models the relationships among variables as a directed acyclic graph using the conditional dependencies among variables. The structure of a BCN can be estimated through use of structure learning algorithms. These algorithms apply an emerging understanding of how directional relationships are predicated on conditional dependence to determine the BCN that best represents the joint probability distributions of a dataset [16]. Assuming that there are no hidden variables unaccounted for, these networks can be interpreted as implying causal relationships [17]. This approach has recently been used to test the direction of effect between binge drinking and prefrontal and temporal gray matter development, finding that atypical gray matter development appeared to be increasing the likelihood of binge drinking rather than binge drinking producing cortical atrophy [18].

The current study used the same BCN modeling approach as Robert et al. [18] with the same IMAGEN data used in Albaugh et al. [1], to assess whether initiation of cannabis use and changing cortical thickness across adolescence are causally related. We did this by including all variables in the analyses of Albaugh et al., as well as several other potential confounders as variables in a BCN. Specially, in our BCN models we included genetic factors putting individuals at risk for cannabis use, demographic factors, life history, psychopathology, and other substance use. Inclusion of this large set of variables was ideal for the analytic strategy planned, as BCN learning algorithms operate best on many interrelated variables, which allows them to determine the conditional dependencies among them.

METHODS

Participants and procedures

Participants were drawn from the IMAGEN study conducted across eight European sites. Local ethics research committees approved the study at each site (London, England: Psychiatry, Nursing and Midwifery Research Ethics Subcommittee, Waterloo Campus, King's College London; Nottingham, England: University of Nottingham Medical School Ethics Committee; Mannheim, Germany: Medizinische Fakultaet Mannheim, Ruprecht Karl Universitaet Heidelberg and Ethik-Kommission II an der Fakultaet fuer Kliniksche Medizin Mannheim; Dresden, Germany: Ethikkommission der Medizinischen Fakultaet Carl Gustav Carus, TU Dresden Medizinische Fakultaet; Hamburg, Germany: Ethics Board, Hamburg Chamber of Physicians; Paris, France: CPP IDF VII (Comité de protection des personnes Ile de France), ID RCB: 2007-A00778-45 September 24, 2007; Dublin, Ireland: TCD School of Psychology REC; and Berlin, Germany: Ethics Committee of the Faculty of Psychology). Written consent was obtained from the adolescent's parent or guardian, and verbal assent was obtained from the adolescent.

The IMAGEN study included 2223 adolescents recruited at age 14 for MRI, genotyping, and self-report data collection who were assessed again 5 years later using the same battery. The final sample of Albaugh et al. (N = 799) was used in the current study, with 162 participants removed for lacking one or more of the additional measures added to this analysis. This resulted in a final sample of 637 participants, which did not differ on any demographic or drug use measure from the sample of Albaugh et al. (p > 0.05). Of note, we also repeated analyses in the exact sample from Albaugh et al. (N = 799) using only the variables included in that study, finding very similar results (shown in Supplementary Fig. 1 and Supplementary Table 1). Of note, participants were selected for the Albaugh et al. [1] study such that all were cannabis naïve at age 14.

Measures

European school survey project on alcohol and drugs. Cannabis use and tobacco use were assessed at age 14 and age 19 with the ESPAD [19], a self-report questionnaire regarding the use of alcohol, nicotine, and cannabis as well as other substances. Participants indicated how many times they had used each of the substances in their lifetime, in the past 12 months, in the past 30 days, and in the past 7 days using a 7-point scale (where 0 indicates never; 1, 1–2 times; 2, 3–5 times; 3, 6–9 times; 4, 10–19 times; 5, 20–39 times; and 6, \geq 40 times). However, since all participants were selected to be cannabis naïve at age 14, only cannabis use at age 19 was included in BCN modeling and other analyses.

Alcohol Use Disorders Identification Test. The Alcohol Use Disorders Identification Test (AUDIT) is a 10-item alcohol screening tool that assesses alcohol consumption, drinking behaviors, and alcohol-associated problems [20]. AUDIT was administered to youths at age 14 and 19. The AUDIT Alcohol Consumption scale (AUDIT-C) was used in the present study and is composed of items on AUDIT that explicitly assess the amount and frequency of alcohol consumption.

Childhood Trauma Questionnaire. The Childhood Trauma Questionnaire (CTQ) is an assessment of adverse experiences occurring during childhood with good validity and internal consistency [21]. This self-report measure contains 70 items that make up five factors: physical abuse, emotional abuse, sexual abuse, physical neglect, and emotional neglect. Responses are on a 5-point Likert-type scale according to the frequency with which an experience occurred, with 1 = "never true" and 5 = "very often true." In the current study, we summed the five factors to create a total score.

Strengths and Difficulties Questionnaire. The Strengths and Difficulties Questionnaire (SDQ) was used to assess symptoms of hyperactivity and inattention [22], which we used as a measure of Attention Deficit/ Hyperactivity Disorder (ADHD) symptoms. The SDQ is a reliable and valid measure of youth emotional and behavior symptoms; scores on the SDQ are predictive of increased probability of clinician-rated psychiatric disorders and it has good retest stability over 4–6 months [23].

2

Substance Use Risk Profile Scale. The Substance Use Risk Profile Scale (SURPS) was used to assess personality traits related to substance use [24]. The SURPS is a 23-item 4-point Likert scale measure that assesses four personality variables: anxiety sensitivity, introversion/hopelessness, impulsivity, and sensation-seeking. From this measure, the trait sensation seeking was selected for BCN modeling, as it was the trait with the largest bivariate relationship with cannabis use at age 19 (r = 0.29 at age 19).

Pubertal Development Scale. Pubertal status was assessed using the pubertal development scale, a self-report measure completed by the participant. This measure has been shown to have good reliability and to correspond with accepted self-report and biological measures of pubertal development [25].

Socioeconomic status. A composite of socioeconomic status (SES) was derived by aggregating: Mother's Education Score, Father's Education Score, Family Stress Unemployment Score, Financial Difficulties Score, Home Inadequacy Score, Neighborhood Score, Financial Crisis Score, Mother Employed Score, and Father Employed Score in a manner consistent with prior work in the IMAGEN dataset [26].

Demographic questionnaire. Children's age, sex, and handedness were measured using a demographic questionnaire completed by their parent/guardian.

Structural MRI. Structural magnetic resonance image (MRI) data were acquired with a 3-dimensional T1-weighted magnetization prepared gradient echo sequence based on the one used in the Alzheimer's Disease Neuroimaging Initiative protocol [27]. These T1 images were processed using the CIVET pipeline (v2.1.0) on the CBRAIN platform using Compute Canada. In the current project, average cortical thickness was extracted from the regions of interest identified in Albaugh et al. that showed a dose-dependent response to cannabis use. This region spanned the left and right dorsomedial and dorsolateral prefrontal cortices and is hereafter referred to as the dorsal prefrontal cortex (DPFC).

For consistency with prior work using BCN modeling in the IMAGEN dataset [18], we used a principal components analysis to create a single variable for cortical thickness in both hemispheres. All variables (cortical thickness, cannabis use, other substance use, age, puberty, polygenic risk score for cannabis use, childhood trauma, socioeconomic status, handedness, and ADHD symptoms) were residualized for site and sex. This single variable was derived from the first principal component. This was done for consistency with recent work using BCN modeling focused on alcohol and brain morphometry in the IMAGEN dataset [18]. This was done for DPFC thickness at age 14 (eigenvalue = 1.8; percent of variance explained = 92%) and the change in DPFC from ages 14 to 19 (eigenvalue = 1.7; percent of variance explained = 87%).

Polygenic risk score. In calculating a polygenic risk score (PRS) for cannabis, genotypes were imputed using the 1000 Genomes Project phase 3 reference panel for Europeans using the Michigan Imputation Server [28]. SNPs that did not meet quality control criteria (Minor Allele Frequency < 0.01; Genotype Call Rate < 95%; Hardy–Weinberg Equilibrium $< 1 \times 10^{-6}$) were excluded. Genetic variants imputed with lower accuracy $(R^2 < 0.6)$, insertion/deletions and palindromic SNPs were excluded, resulting in 5,183,147 SNPs. The PRS was calculated based on a genomewide association study (GWAS) conducted in an independent sample. This GWAS described the genetic correlates of total lifetime frequency of cannabis use using data from the International Cannabis Consortium, UK Biobank, and 23andMe datasets [29]. All participants (53,179 cases and 131,586 controls) included in the GWAS were of European Ancestry, as are all participants in the present analysis. This PRS was calculated using PLINK 2.0 [30]. Index variants were identified by clumping using an r2 threshold of 0.1 with a 1000 kb window using the 1000 Genomes (EUR) as reference. The available summary statistics for this GWAS included 11,535,788 SNPs. After quality control procedures (i.e., removal of indels and palindromic SNPs and retention of SNPs that overlap with those available for the target sample) we had 4,595,692 SNPs, of which 145,015 remained after clumping for use in the PRS. No p-value threshold from the GWAS was used for the association of SNPs to cannabis use (i.e., p = 1.0 was used as the threshold in PRSlice).

Analyses

To determine the relationship of variables to each other outside of BCN modeling, we also conducted bivariate Pearson's correlations between all variables used in BCN analyses.

Then BCN analyses were conducted using the package bnlearn [16] in R following a template of the analyses conducted in Robert et al. [18]. Code for this study is available at https://github.com/owensmax/ Cannabis_Bayesian_Networks. First, a list of "blacklisted" pathways was set (Supplementary Table 2), which are pathways that cannot exist for logical reasons (e.g., age 19 cannabis use affecting sex at birth). Then the structure learning algorithms were applied to derive directed acyclic graphs representing the directional relationships between variables. To derive statistics on the BCN models, the algorithms were run 10,000 times with bootstrap re-sampling (i.e., samples drawn randomly with replacement) for samples 100% of the size of the entire dataset. From these bootstrapped BCN models a summary model is derived aggregating their results. The strength of a connection between two variables was determined as the percentage of the bootstrapped BCN models in which a connection was present. The direction of a connection was determined as the percentage of models with a connection in which the connection was directed from one variable to another. To ensure a sparse model containing only robust connections, we thresholded all models resulting from structure learning algorithms such remove connections with strength under 90%. Of note, this was primarily a choice made for visualization purposes and did not affect the structure learning process.

We conducted BCN analyses using three different types of structure learning algorithms. In score-based algorithms, the presence and direction of the relationships between variables are determined by testing numerous, randomly generated potential BCN models to evaluate which configuration of directed edges has the best model fit [31, 32]. In constraint-based algorithms, the specific tools used to determine the directional relationship between variables are statistical independence tests, which are combined with known rules about how the joint probability of three variables provides information about their directional relationship [32, 33]. In hybrid algorithms, key elements of score-based and constraint-based algorithms are combined to leverage the strengths of each approach.

To assess the consistency of results, we tested numerous structure learning algorithms from the three domains of algorithm: score-based, constraint-based, and hybrid [32, 34]. Our strategy was to extensively test algorithms from each of the three major BCN structure learning algorithm classes using a variety of options and parameters [32]. The algorithms and parameters tested are shown in Table 2. In doing this, we picked the most established algorithm in each class and created BCNs with that algorithm using a variety of approaches. Then we tested a second algorithm within these same classes using that approach's default settings only. For the score-based models we used the hill climbing algorithm as the primary approach and the tabu algorithm as the secondary approach. For the constraint-based models we used the grow-shrink algorithm as the primary approach and the incremental association Markov blanket algorithm as the secondary approach. For the hybrid models, we used the max-min hill climbing algorithm as the primary approach and the rsmax2 algorithm as the secondary approach.

As noted, we repeated the primary analyses from the score-based algorithm approach (i.e., hill climbing) and the constraint-based algorithm approach (i.e., grow-shrink) using different values for key modifiable parameters. For the hill climbing algorithm, the specific fit index by which the model fit is assessed is critical to the validity of this approach. Our primary analysis used the Bayesian Information Criterion as the fit index, which is among the most common and interpretable of these criteria [35]. Additionally, a secondary analysis used the Akaike Information Criterion as the fit index. Another flexible parameter for the hill climbing algorithm is the starting point for model building. In our primary analysis the hill climbing algorithm started from an empty BCN, but in a separate secondary analysis the hill climbing algorithm started from a randomly generated BCN. Additionally, perturbations can be randomly introduced to the hill climbing algorithm to reduce the chance of landing at a local minimum. Thus, in another secondary analysis, we introduced random perturbations of the BCN to our primary analysis's hill climbing procedure. For the grow-shrink algorithm, the most flexible parameter is the test used to determine dependence/independence. Our primary dependence test was the mutual information test, which determines the amount of information that can be obtained about one random variable by observing the other random variable [36]. However, in two separate secondary

analyses we used two other common independence tests: the Fisher Z test and the Pearson's correlation.

In addition to these analyses, we also built models using our primary algorithm (hill climbing) with one direction between cannabis use and DPFC thickness "blacklisted". By testing both backlisted directions in separate models, we were able to compare the two model's fit statistics as another means of evaluating the directional relationship between these two variables.

RESULTS

Preliminary analyses

Pearson's correlation analyses are reported in Table 1. As expected from Albaugh et al., change in cortical thickness in the dorsal prefrontal (DPFC) region of interest between ages 14 and 19 was associated with cannabis use during that same period (r = -0.17, p = 1e-5). Of note, a cannabis use PRS [29] was associated with cannabis use levels reported at age 19 (r = 0.10, p = 0.02).

Bayesian network results

All BCN modeling algorithms yielded similar patterns of connections with similar coefficients. Figure 1 shows the summary model from our primary analysis, which aggregates across the 10,000 bootstrapped resampling to yield strength and direction coefficients. This model used the hill climbing algorithm starting from an empty graph with Bayesian information criterion as the goodness of fit metric and found that cannabis use was affecting DPFC thickness in 96% of models. Notably, cannabis use was the only variable directly affecting DPFC thickness. Also noteworthy, despite their relationship in bivariate correlations, the cannabis use PRS did not show a direct link to cannabis use in BCN modeling.

Strength and direction coefficients for the cannabis use to DPFC thickness connection across all models are shown in Table 2. Additionally, for all modeling approaches used, model coefficients with greater than 60% strength are reported in Supplementary Tables 3-12. Our primary model, Hill Climbing, is also visualized including all coefficients with strength greater than 60% in Supplementary Fig. 2. For all score-based algorithms, the connection from cannabis use to DPFC thickness had a strength ranging from 99% to 100% and a direction ranging from 91% to 96%. Similar results were found across constraint-based algorithms, with the connection from cannabis use to DPFC thickness having strength ranging from 91% to 97% and direction ranging from 81% to 82%. The two-hybrid algorithms, Max-min hill climbing and RSMAX2, showed comparable results to the scorebased algorithms, finding strength values of 92%/93% and direction values of 95% in these algorithms. In analyses with one direction restricted (i.e., "blacklisted") between DPFC thickness and cannabis use, the model in which cannabis use was only allowed to affect DPFC thickness had a better fit than the model in which DPFC thickness was only allowed to affect cannabis use $(\Delta BIC = 5.2).$

DISCUSSION

In using BCN modeling to attempt to disentangle the directionality of the relationship between adolescent cannabis use and DPFC thinning, the current study's results were overwhelmingly supportive of the conclusion that adolescent cannabis use affects DPFC thickness rather than the alternative hypotheses that DPFC thickness development affects an adolescent's likelihood of beginning to use cannabis or that the two are not affecting one another. To ensure stability of the results, we tested two algorithms from each of the three BCN structure learning classes using a variety of analytic approaches for each algorithm. In addition to these bottom-up approaches to model building, we also used a top-down model building strategy that pre-specified

Table 1. Pearson correlation	v among v	⁄ariables us	ed in the	Bayesian Ne	etwork mo	deling.										
	٢	2	m	4	S	9	7	8	6	10	11	12	13	14	15	16
1. Baseline DPFC Thickness																
2. Change DPFC Thickness	-0.50															
3. Change Cannabis Use	-0.04	-0.17														
4. Tobacco Use Baseline	-0.14	0.04	0.26													
5. Change Tobacco Use	-0.03	-0.09	0.49	-0.05												
6. Alcohol Use Baseline	-0.06	-0.02	0.26	0.39	0.19											
7. Change Alcohol Use	0.03	-0.08	0.19	-0.13	0.28	-0.32										
8. Handedness	-0.02	0.03	0.01	0.05	-0.06	0	-0.02									
9. Baseline Age	-0.13	0.10	-0.03	0.04	-0.09	0.05	-0.05	-0.04								
10. Cannabis PRS	-0.01	-0.01	0.10	-0.05	0.11	0.06	0.07	-0.07	-0.02							
11. SES	0.06	-0.04	0.02	-0.17	-0.06	-0.04	0.08	-0.01	-0.07	0.05						
12. Pubertal Development	0	0.09	0	0.03	0.05	0.17	-0.08	-0.02	0.23	-0.05	0.02					
13. ADHD Baseline	0.04	-0.11	0.11	0.06	0.13	0.12	0.06	-0.01	-0.08	0.04	-0.10	-0.08				
14. Change ADHD	-0.01	0.04	0	-0.04	0.03	-0.10	0.08	-0.01	0.01	0.04	0.02	0.02	-0.56			
15. Childhood Trauma	-0.03	0.01	0.02	0.05	-0.01	0.01	-0.02	0.07	0.01	0.01	-0.08	-0.05	0	0.05		
16. SS	-0.11	0	0.16	0.14	0.13	0.23	0.02	-0.02	-0.04	0.01	0	0.10	0.08	-0.02	-0.03	
17. Change SS	0.09	-0.05	0.09	-0.08	0.07	-0.10	0.17	-0.03	-0.08	0.05	0	-0.06	0.06	0.04	0.04	-0.49
All variables were residualized PRS Cannabis use polygenic r. 14 to 19.	l for site and isk score, <i>DF</i>	d sex. Bold ᠈FC dorsal p	text indica refrontal th	tes <i>p</i> < 0.05. nickness, <i>SE</i> S	Socioecon	omic Status	, ADHD atte	ention/defic	cit-hyperacti	vity disord	er, SS sensa	tion seekin	ig, Change c	change in a	variable fro	im ages



Bayesian Causal Network - Hill Climbing Algorithm

Fig. 1 Primary Analysis: Bayesian network model from the hill climbing algorithm. Boxes represent variables used in Bayesian Causal Network models. Yellow boxes are age 14 variables, green boxes are change from age 14 to 19 variables, and blue boxes are other variables of interest. Lines indicate a dependent relationship between two variables in at least 90% of 10,000 bootstrapped models (i.e., strength \geq 90%). Arrows indicate directional of relationship found between two variables. S = strength, representing the percentage of bootstrapped models in which a dependent relationship was present. D = direction, representing the percentage of bootstrapped models with a dependent relationship in which a connection was in the direction shown in the figure. (f) = connection with direction pre-specified to fit with temporal ordering. Note: all participants were cannabis-naïve at age 14. All variables were residualized for site and sex.

the relationship between cannabis use and change in DPFC thickness to test which showed a better model fit. BCNs built using every algorithm and parameter combination indicated cannabis was affecting DPFC thickness, with most models finding this in over 90% of bootstrap samples and all models finding this in over 80% of bootstrap samples. Score-based and constraint-based approaches to BCN construction are sufficiently unique that their convergence in the current study adds to the confidence of these results. Thus, the consistency of results among these approaches is compelling evidence in favor of a causal relationship of adolescent cannabis use on DPFC thickness.

One notable feature of the models constructed is that the strength of the relationship between cannabis use and DPFC thickness was expected given how the region was chosen: the region of DPFC that we used was selected specifically because it was found in our previous work to be related to cannabis use [1]. Therefore, it was unsurprising that the strength of the connection between cannabis use and DPFC thinning from ages 14 to 19 was 100%. However, what is notable in the current results is that the direction of this relationship was so consistently found to go from cannabis use to cortical thickness. This was not explored in our previous analyses and represents the unique contribution of this study.

There are several relationships noteworthy for being present or absent in the current findings. Many connections identified by the BCN algorithms were expected based on existing literature. For instance, low socioeconomic status showed a directional effect on smoking at age 14, which is consistent with a robust literature linking smoking to low socioeconomic status [37]. Likewise, early pubertal development showed a directional relationship with age 14 alcohol use, as has been shown previously [38]. However, there were also expected relationships not present. One of these was a relationship between the cannabis PRS and cannabis use. Despite its bivariate association with cannabis use (r = 0.10), the PRS for cannabis use was not associated with cannabis use in any BCN

model. This is because BCN models report the relationship between variables in the context of all other variables in the model, suggesting that other factors in the model better explain the likelihood of cannabis use. The lack of associations of the cannabis PRS with cannabis use or DPFC thickness is evidence against an alternate explanation that a pre-existing genetic trajectory causally affects DPFC thinning and cannabis use in a confounding manner. There were also some expected relationships that were not observed in our main model but were found when the strength threshold was lowered to 60%, as reported in Supplementary Tables 3-12. For example, there was a directional relationship from ADHD symptoms at age 14 to alcohol use at age 14, suggesting that ADHD may have a weak directional effect on alcohol use. Further, it should be noted that the current results differ from the observed relationship between alcohol use and brain structure using BCN structure learning algorithms conducted by Robert et al. [18]. In that study, BCN structure learning algorithms overwhelmingly indicated that volume reduction in the prefrontal and temporal cortices was causally affected by alcohol consumption in adolescents from the IMAGEN study. The discrepancy between that study and the current one illustrates that BCN algorithms can arrive at quite different results in similar situations.

Given their importance to the current study, it is worth considering how BCN structure learning algorithms estimate the directional relationships between variables. These algorithms apply an emerging understanding of how directional relationships are predicated on conditional dependence to determine the BCN that best represents the joint probability distributions of a dataset [16]. In score-based algorithms, the presence and direction of the relationships between variables are determined by testing numerous, randomly generated potential BCN models to evaluate which configuration of directed edges has the best model fit [31, 32]. In constraint-based algorithms, the specific tools used to determine the directional relationship between variables are

Table 2. Summary of Bayesian	causal network analytic approaches cor	nducted.				
SCORE-BASED ALGORITHMS						
Algorithm	Fit criterion	Start Point	Random Perturbations	Independence Test	Strength	Direction
*Hill Climbing	Bayesian Information Criterion	Empty Graph	No	1	100%	96%
Hill Climbing	Akaike Information Criterion	Empty Graph	No		100%	95%
Hill Climbing	Bayesian Information Criterion	Random Graph	No		%66	91%
Hill Climbing	Bayesian Information Criterion	Empty Graph	Yes	1	100%	95%
Tabu	Bayesian Information Criterion	Empty Graph	No	1	100%	95%
CONSTRAINT-BASED ALGORITI	SMF					
Algorithm	Fit criterion	Start Point	Random Perturbations	Independence Test	Strength	Direction
Grow-Shrink	T	,	T	Mutual Information Test	97%	82%
Grow-Shrink	1			Fisher Z Test	91%	81%
Grow-Shrink	I	,	T	Pearson Correlation	97%	82%
IAMB	1	,	T	Mutual Information Test	96%	82%
HYBRID ALGORITHMS						
Algorithm	Fit criterion	Start Point	Random Perturbations	Independence Test	Strength	Direction
Max-Min Hill Climbing	Bayesian Information Criterion	Empty Graph	No	Mutual Information Test	93%	95%
RSMAX2	Bayesian Information Criterion	Empty Graph	No	Mutual Information Test	92%	95%
"-" represents cells that are not a	pplicable. The asterisked row (*) correspon	nds with the graph in Fig. 1				

statistical independence tests, which are combined with known rules about how the joint probability of three variables provides information about their directional relationship [32, 33]. In hybrid algorithms, key elements of score-based and constraint-based algorithms are combined to leverage the strengths of each approach. Score-based and constraint-based approaches to BCN construction are sufficiently unique that their convergence in the current study adds to our confidence in these results. Within the assumptions and constraints of the methodology, BCN models offer a complementary approach to infer probable causal associations from amidst the complex, confounded, and colinear measurements that so typically characterizes nonexperimental human research.

One important limitation of these findings is that BCN modeling estimates the direction of a relationship only in the context of the variables included in its models: BCN modeling is not able to detect hidden or unmeasured variables that may be affecting the variables within the model and, consequently, like most statistical methods, is susceptible to unmeasured confounders. The present analysis did include many relevant variables in the BCN model that represent obvious potential confounding factors, including demographics, genetics, psychopathology, personality, childhood adversity, and measures of other substance use. While there are, of course, an infinitely large number of potential confounders, the current analysis suggests that in the context of many of the most likely confounders, there is a directional relationship from adolescent cannabis use to dorsal prefrontal cortical thickness that is consistent with causality. However, it remains possible that some unmeasured confounder could alter these results. Considering this, we suggest that the best way to conceive of the present approach is that it addresses a central, but unresolved, question on the directionality of the previously observed association between cannabis use and dorsal prefrontal cortex thickness, but that it does so within the confines of the specific (and necessarily finite) number of confounders that were included. While certainly not definitive, the present results provide a thorough initial test of this question using BCNs, finding results highly supportive of a causal effect of cannabis on brain development. We hope that future work, whether employing causal modeling or not, further investigates this matter and continues to evaluate other potential confounding variables.

Another consideration is that the association between DPFC thinning and cannabis use was still relatively small, r = 0.17 in bivariate analyses. This suggests that there is much more than cannabis use that goes into cortical development and other important psychological and social contributors to development should not be overlooked. Of note, cannabis use was assessed in the current study using a retrospective, self-report measure and its possible that with a more thorough measure (e.g., ecological momentary assessment of cannabis use) the effect sizes seen in bivariate analyses may have been larger. However, a correlation of 0.17 is not insignificant either, particularly when compared to other meaningful effect sizes found in similar datasets [39].

Prior research has estimated normative cortical thinning of around 1% annually, which comes out to around 0.03–0.06 mm per year [8–11]. Results of the current study were highly consistent with this prior literature, as the average percent reduction in cortical thickness from ages 14 to 19 was 3.6% (i.e., 0.12 mm reduction in thickness). In cannabis-using participants, the average percent reduction was 4.4% (0.14 mm reduction in thickness), compared to an average reduction of 3.1% in cannabis abstinent participants (a 0.10 mm reduction in thickness). The heaviest using participants (those who used cannabis 40 or more times between the ages of 14 and 19) demonstrated a 5% reduction in cortical thickness (i.e., 0.17 mm reduction in thickness), while the lightest using participants (those reporting fewer than 10 uses between the ages of 14 and 19) showed a 4.1% reduction (0.13 mm). Compared to those who did not use cannabis, this represents a 30% greater reduction in cortical thickness in all cannabis-using participants, a 24% greater reduction in the lightest using participants, and a 38% greater reduction in the heaviest using participants. Notably, differences in rate of thinning comparable to those found in the current manuscript have been noted as signifying greater risk of depression in adolescents in other work [14]. Thus, while noting that the quantification of cortical thinning is imperfect, resting on MRI contrast images [40], we think that these findings do suggest an association sufficiently large to merit concern.

The present results report a notable association between DPFC thinning and cannabis use in a dose-dependent manner. While noting again the caveats associated with inferring causation from human research, these findings complement other humans [1, 3, 4, 7, 41] and animal [5] research and add to the increasingly compelling evidence base that adolescent cannabis use affects brain development.

REFERENCES

- Albaugh MD, Ottino-Gonzalez J, Sidwell A, Lepage C, Juliano A, Owens MM, et al. Cannabis use during adolescence is associated with neurodevelopment. JAMA Psychiatry. 2021;78:1031–40.
- Scott JC, Slomiak ST, Jones JD, Rosen AF, Moore TM, Gur RC. Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry. 2018. https://doi.org/ 10.1001/jamapsychiatry.2018.0335.
- Chye Y, Christensen E, Yücel M. Cannabis use in adolescence: a review of neuroimaging findings. J Dual Diagn. 2020;16:83–105.
- French L, Gray C, Leonard G, Perron M, Pike GB, Richer L, et al. Early cannabis use, polygenic risk score for schizophrenia, and brain maturation in adolescence. JAMA Psychiatry. 2015;72:1002.
- 5. Miller ML, Chadwick B, Dickstein DL, Purushothaman I, Egervari G, Rahman T, et al. Adolescent exposure to Δ 9 -tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture of prefrontal pyramidal neurons. Mol Psychiatry. 2019;24:588–600.
- Schaefer JD, Hamdi NR, Malone SM, Vrieze S, Wilson S, McGue M, et al. Associations between adolescent cannabis use and young-adult functioning in three longitudinal twin studies. Proc Natl Acad Sci. 2021;118:e2013180118.
- Ross JM, Ellingson JM, Rhee SH, Hewitt JK, Corley RP, Lessem JM, et al. Investigating the causal effect of cannabis use on cognitive function with a quasiexperimental co-twin design. Drug Alcohol Depend. 2020;206:107712.
- 8. Zhou D, Lebel C, Treit S, Evans A, Beaulieu C. Accelerated longitudinal cortical thinning in adolescence. Neuroimage. 2015;104:138–45.
- Tamnes CK, Herting MM, Goddings AL, Meuwese R, Blakemore SJ, Dahl RE, et al. Development of the cerebral cortex across adolescence: a multisample study of inter-related longitudinal changes in cortical volume, surface area, and thickness. J Neurosci. 2017. https://doi.org/10.1523/JNEUROSCI.3302-16.2017.
- Alemán-Gómez Y, Janssen J, Schnack H, Balaban E, Pina-Camacho L, Alfaro-Almagro F, et al. The human cerebral cortex flattens during adolescence. J Neurosci. 2013;33:15004.
- Parker N, Patel Y, Jackowski AP, Pan PM, Salum GA, Pausova Z, et al. Assessment of neurobiological mechanisms of cortical thinning during childhood and adolescence and their implications for psychiatric disorders. JAMA Psychiatry. 2020;77:1127–36.
- Busso DS, McLaughlin KA, Brueck S, Peverill M, Gold AL, Sheridan MA. Child abuse, neural structure, and adolescent psychopathology: a longitudinal study. J Am Acad Child Adolesc Psychiatry. 2017;56:321.
- Shaw P, Gilliam M, Liverpool M, Weddle C, Malek M, Sharp W, et al. Cortical development in typically developing children with symptoms of hyperactivity and impulsivity: support for a dimensional view of attention deficit hyperactivity disorder. Am J Psychiatry. 2011. https://doi.org/10.1176/appi.ajp.2010.10030385.
- Bos MGN, Peters S, Van De Kamp FC, Crone EA, Tamnes CK. Emerging depression in adolescence coincides with accelerated frontal cortical thinning. J Child Psychol Psychiatry. 2018;59:994–1002.
- Pearl J. Probabilistic reasoning in intelligent systems: networks of plausible inference. Los Altos: Morgan Kaufmann; 1988.
- Scutari M. Learning Bayesian networks with the bnlearn R Package. J Stat Softw. 2010;35:1–22.
- 17. Pearl J. Causality: models, reasoning and inference. 2nd ed. Cambridge: Cambridge University Press; 2009.
- Robert GH, Luo Q, Yu T, Chu C, Ing A, Jia T, et al. Association of gray matter and personality development with increased drunkenness frequency during adolescence. JAMA Psychiatry. 2020;77:409–19.

- Hibell B, Andersson B, Bjarnason T, Ahlström S, Balakireva O, Kokkevi A, et al. The ESPAD report 2003: alcohol and other drug use among students in 35 European countries. Swedish Council for Information on Alcohol and Other Drugs, 2004.
- Reinert DF, Allen JP. The alcohol use disorders identification test: an update of research findings. Alcohol Clin Exp Res. 2007;31:185–99.
- Bernstein DP, Ahluvalia T, Pogge D, Handelsman L. Validity of the childhood trauma questionnaire in an adolescent psychiatric population. J Am Acad Child Adolesc Psychiatry. 1997;36:340–8.
- Goodman R. The strengths and difficulties questionnaire: a research note. J Child Psychol Psychiatry. 1997;38:581–6.
- Goodman R. Psychometric properties of the strengths and difficulties questionnaire. J Am Acad Child Adolesc Psychiatry. 2001. https://doi.org/10.1097/ 00004583-200111000-00015.
- Woicik PA, Stewart SH, Pihl RO, Conrod PJ. The Substance Use Risk Profile Scale: a scale measuring traits linked to reinforcement-specific substance use profiles. Addict Behav. 2009;34:1042–55.
- Petersen AC, Crockett L, Richards M, Boxer A. A self-report measure of pubertal status: reliability, validity, and initial norms. J Youth Adolesc. 1988. https://doi.org/ 10.1007/BF01537962.
- Whelan R, Watts R, Orr CA, Althoff RR, Artiges E, Banaschewski T, et al. Neuropsychosocial profiles of current and future adolescent alcohol misusers. Nature. 2014;512:185–9.
- ADNI. MRI scanner protocols. http://adni.loni.usc.edu/methods/documents/mriprotocols/. Accessed 15 Oct 2021.
- 28. Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48:1284.
- Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nat Neurosci. 2018;21:1161–70.
- Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.
- Scutari M, Graafland CE, Gutiérrez JM. Who Learns Better Bayesian Network Structures: Constraint-Based, Score-based or Hybrid Algorithms? Proceedings of the Ninth International Conference on Probabilistic Graphical Models. In *Proc Machine Learning Res.* 2018;72:416–27 Available from https://proceedings.mlr. press/v72/scutari18a.html.
- Margaritis D. Learning Bayesian Network Model Structure from Data. Carnegie Mellon University. 2003. Available from https://www.cs.cmu.edu/~dmarg/Papers/ PhD-Thesis-Margaritis.pdf.
- 33. Tsamardinos I, Aliferis CF, Statnikov A. Algorithms for large scale Markov blanket discovery. 2003 www.aaai.org. Accessed 23 Mar 2021.
- Nagarajan R, Scutari M, Lebre S. Bayesian networks in R. New York, NY: Springer; 2013.
- 35. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6:461-4.
- Cover TM, Thomas JA. Elements of Information Theory (2nd Ed.), Wiley-Interscience. New York, NY, 2006.
- Hanson MD, Chen AE. Socioeconomic status and health behaviors in adolescence: a review of the literature. J Behav Med. 2007;30:263–85.
- Wichstrøm L. The impact of pubertal timing on adolescents' alcohol use. J Res Adolesc. 2001;11:131–50.
- Owens MM, Potter A, Hyatt CS, Albaugh M, Thompson WK, Jernigan T, et al. Recalibrating expectations about effect size: a multi-method survey of effect sizes in the ABCD study. PLoS One. 2021. https://doi.org/10.1371/journal. pone.0257535.
- Natu VS, Gomez J, Barnett M, Jeska B, Kirilina E, Jaeger C, et al. Apparent thinning of human visual cortex during childhood is associated with myelination. Proc Natl Acad Sci. 2019;116:20750–9.
- Morin J-FG, Afzali MH, Bourque J, Stewart SH, Séguin JR, O'Leary-Barrett M, et al. A population-based analysis of the relationship between substance use and adolescent cognitive development. Am J Psychiatry. 2018;176:98–106. https://doi. org/10.1176/appi.ajp2018.18020202.

ACKNOWLEDGEMENTS

The IMAGEN consortium includes: Tobias Banaschewski, M.D., Ph.D.; Gareth J. Barker, Ph.D.; Arun L.W. Bokde, Ph.D.; Sylvane Desrivières, Ph.D.; Herta Flor, Ph.D.; Antoine Grigis, Ph.D.; Hugh Garavan, Ph.D.; Penny Gowland, Ph.D.; Andreas Heinz, M.D., Ph.D.; Rüdiger Brühl, Ph.D.; Jean-Luc Martinot, M.D., Ph.D.: Marie-Laure Paillère Martinot, M. D., Ph.D./Eric Artiges, M.D., Ph.D.; Frauke Nees, Ph.D; Dimitri Papadopoulos Orfanos, Ph.D., Herve Lemaitre, Ph.D; Tomáš Paus, M.D., Ph.D.; Luise Poustka, M.D., Sasina Hohmann, M.D., Sabina Millenet, PhD; Juliane H. Fröhner, MSc; Michael N. Smolka, M. D; Henrik Walter, M.D., Ph.D.; Robert Whelan, Ph.D.; Gunter Schumann, M.D. ImagenPathways "Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways" is a collaborative project supported by the M.M. Owens et al.

European Research Area Network on Illicit Drugs (ERANID). This paper is based on independent research commissioned and funded in England by the National Institute for Health Research (NIHR) Policy Research Programme (project ref. PR-ST-0416-10001). The views expressed in this article are those of the authors and not necessarily those of the national funding agencies or ERANID.

AUTHOR CONTRIBUTIONS

MMO conceptualized the study, conducted the Bayesian causal network analyses, and drafted the manuscript. HG supervised the study and assisted in conceptualization, interpretation, drafting, and editing of the manuscript. MDA conducted preliminary analyses, assisted with study conceptualization and interpretation of the results, and edited the manuscript. NA, DY, and SH assisted in the conceptualization of the study and interpretation of the results, as well as editing the manuscript. RW, RBC, SM, and PAS assisted with the analysis of the data and revision of the manuscript. AJ assisted with data management and interpretation of results. All consortium members contributed to the conceptualization, design, and conducting of the IMAGEN study from which the data used were drawn and approved the final manuscript, including TB, ALWB, SD, HF, AG, PG, AH, RB, J-LM, M-LPM, EA, FN, DPO, HL, TP, LP, SM, JHF, MNS, HW, RW, and GS.

COMPETING INTERESTS

This work was funded by NIH/NIDA T32DA043593 and R01DA047119. MDA is supported by K08 MH121654 and a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation. This work received support from the following sources: the European Union-funded FP6 Integrated Project IMAGEN (Reinforcementrelated behavior in normal brain function and psychopathology) (LSHM-CT- 2007-037286), the Horizon 2020 funded EBC Advanced Grant "STRATIEY" (Brain network based stratification of reinforcement-related disorders) (695313), Human Brain Project (HBP SGA 2, 785907, and HBP SGA 3, 945539), the Medical Research Council Grant "c-VEDA" (Consortium on Vulnerability to Externalizing Disorders and Addictions) (MR/N000390/1), the National Institute of Health (NIH) (R01DA049238, A decentralized macro and micro gene-by-environment interaction analysis of substance use behavior and its brain biomarkers), the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, the Bundesministeriumfür Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B: Forschungsnetz IMAC-Mind 01GL1745B), the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1), the Medical Research Foundation and Medical Research Council (grants MR/R00465X/1 and MR/ S020306/1), the National Institutes of Health (NIH) funded ENIGMA (grants 5U54EB020403-05 and 1R56AG058854-01), NSFC grant 82150710554 and environ-MENTAL grant. Further support was provided by grants from: - the ANR (ANR-12-SAMA-0004, AAPG2019 - GeBra), the Eranet Neuron (AF12-NEUR0008-01 - WM2NA; and ANR-18-NEUR00002-01 - ADORe), the Fondation de France (00081242), the Fondation pour la Recherche Médicale (DPA20140629802), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives (MILDECA), the

THE IMAGEN CONSORTIUM

Assistance-Publique-Hôpitaux-de-Paris and INSERM (interface grant), Paris Sud University IDEX 2012, the Fondation de l'Avenir (grant AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the National Institutes of Health, Science Foundation Ireland (16/ERCD/3797), U.S.A. (Axon, Testosterone and Mental Health during Adolescence: RO1 MH085772-01A1) and by NIH Consortium grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence. TB served in an advisory or consultancy role for Lundbeck. Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire. He received conference support or speaker's fee by Lilly, Medice, Novartis, and Shire. He has been involved in clinical trials conducted by Shire & Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is unrelated to the above grants and relationships. Dr. Barker has received honoraria from General Electric Healthcare for teaching on scanner programming courses. LP served in an advisory or consultancy role for Roche and Viforpharm and received speaker's fee by Shire. She received royalties from Hogrefe, Kohlhammer, and Schattauer. The present work is unrelated to the above grants and relationships. The other authors report no biomedical financial interests or potential conflicts of interest.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-022-01956-4.

Correspondence and requests for materials should be addressed to Max M. Owens.

Reprints and permission information is available at http://www.nature.com/ reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.

© The Author(s) 2022

Tobias Banaschewski²⁹, Gareth J. Barker³⁰, Arun L. W. Bokde³¹, Sylvane Desrivières³², Herta Flor^{33,34}, Antoine Grigis³⁵, Hugh Garavan³⁶, Penny Gowland³⁷, Andreas Heinz³⁸, Rüdiger Brühl³⁹, Jean-Luc Martinot⁴⁰, Marie-Laure Paillère Martinot^{41,42}, Eric Artiges⁴³, Frauke Nees^{29,33,44}, Dimitri Papadopoulos Orfanos³⁵, Herve Lemaitre^{35,45}, Tomáš Paus^{46,47}, Luise Poustka⁴⁸, Sarah Hohmann²⁹, Sabina Millenet²⁹, Juliane H. Fröhner⁴⁹, Michael N. Smolka⁴⁹, Henrik Walter³⁸, Robert Whelan⁵⁰ and Gunter Schumann^{51,52}

²⁹Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany. ³⁰Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. ³¹Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland. ³²Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, London, UK. 33 Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, Mannheim, Germany. 34Department of Psychology, School of Social Sciences, University of Mannheim, 68131 Mannheim, Germany. 35 NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France. 36 Departments of Psychiatry and Psychology, University of Vermont, 05405 Burlington, VT, USA. ³⁷Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK. ³⁸Department of Psychiatry and Psychotherapy CCM, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. ³⁹Physikalisch-Technische Bundesanstalt (PTB), Braunschweig and Berlin, Braunschweig, Germany. ⁴⁰Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Gif-sur-Yvette, France. 41 Institut National de la Santé et de la Recherce Médicale, INSERM U A10 "Trajectoires développementales & psychiatrie", University Paris-Saclay, Ecole Normale Supérieure Paris-Saclay, CNRS; Centre Borelli, Gif-sur-Yvette, France. ⁴²AP-HP. Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France. 43 Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en Psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Gif-sur-Yvette; and Psychiatry Department, EPS Barthélémy Durand, Etampes, France. 44 Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, Kiel, Germany.⁴⁵Institut des Maladies Neurodégénératives, UMR 5293, CNRS, CEA, Université de Bordeaux, 33076 Bordeaux, France. ⁴⁶Department of Psychiatry, Faculty of Medicine and Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, QC,

8

Canada. ⁴⁷Departments of Psychiatry and Psychology, University of Toronto, Toronto, ON, Canada. ⁴⁸Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen, von-Siebold-Str. 5, 37075 Göttingen, Germany. ⁴⁹Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany. ⁵⁰School of Psychology and Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland. ⁵¹Centre for Population Neuroscience and Stratified Medicine (PONS), Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Germany. ⁵²Centre for Population Neuroscience and Precision Medicine (PONS), Institute for Science and Technology of Brain-inspired Intelligence (ISTBI), Fudan University, Shanghai, China.